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Abstract
Background. To investigate the impacts of depression screening, diagnosis and treatment on
major adverse cardiac events (MACEs) in acute coronary syndrome (ACS).
Methods. Prospective cohort study including a nested 24-week randomised clinical trial for
treating depression was performed with 5–12 years after the index ACS. A total of 1152
patients recently hospitalised with ACS were recruited from 2006 to 2012, and were divided
by depression screening and diagnosis at baseline and 24-week treatment allocation into five
groups: 651 screening negative (N), 55 screening positive but no depressive disorder (S), 149
depressive disorder randomised to escitalopram (E), 151 depressive disorder randomised to
placebo (P) and 146 depressive disorder receiving medical treatment only (M).
Results. Cumulative MACE incidences over a median 8.4-year follow-up period were 29.6% in
N, 43.6% in S, 40.9% in E, 53.6% in P and 59.6% in M. Compared to N, screening positive was
associated with higher incidence of MACE [adjusted hazards ratio 2.15 (95% confidence inter-
val 1.63–2.83)]. No differences were found between screening positive with and without a for-
mal depressive disorder diagnosis. Of those screening positive, E was associated with a lower
incidence of MACE than P and M. M had the worst outcomes even compared to P, despite
significantly milder depressive symptoms at baseline.
Conclusions. Routine depression screening in patients with recent ACS and subsequent
appropriate treatment of depression could improve long-term cardiac outcomes.
Introduction
Depression is common in acute coronary syndrome (ACS) including myocardial infarction
(MI) and unstable angina. Comorbid depression has been robustly associated with poor prog-
nosis of ACS including increased mortality and non-fatal events (Nicholson, Kuper, &
Hemingway, 2006). Since ACS and depression are two leading causes of disability (Mathers,
Fat, & Boerma, 2008), their comorbidity may generate a high disease burden. Accordingly,
the screening and treatment of depression have been considered as potentially important,
although there has been no consensus on applying this procedure to real clinical practice
for patients with ACS.
In 2008, the American Heart Association (AHA) Science Advisory recommended routine
screening for depression in patients with ACS considering the deleterious effects of depression
on ACS prognosis (Lichtman et al., 2008). However, shortly afterward, a systematic review
found no evidence for or against the recommendations that depression should be evaluated
or that screening for depression should be considered as part of standard care in patients
with ACS (Thombs et al., 2008). This argument was strongly influenced by the lack of evidence
for significant beneficial effects of antidepressant or cognitive behavioural treatment for
depression on long-term cardiac outcomes in patients with ACS (Berkman et al., 2003;
Glassman, Bigger, & Gaffney, 2009; van Melle et al., 2007). On the one hand, the need for
appropriate screening guidelines has been highlighted because depression is an important car-
diac risk marker, is a treatable condition, and its presence warrants more aggressive cardiac
care and secondary prevention efforts regardless of whether treating depression can improve
cardiac outcomes (Carney, Freedland, & Jaffe, 2009). On the other hand, there have been
https://doi.org/10.1017/S003329171900388X
Downloaded from https://www.cambridge.org/core. King's College London, on 28 Jan 2020 at 15:47:41, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
additional calls for reassessing AHA recommendations for routine
screening of depression because of the extra time and cost
involved (Thombs et al., 2013; Ziegelstein, Thombs, Coyne, &
de Jonge, 2009), particularly given the pressing need for treatment
of ACS in its acute phase (Anderson et al., 2013), and the high
costs associated with ACS (Benjamin et al., 2018).
Recently evidence has emerged on potential beneficial effects of
treating depression on cardiac prognosis in ACS. In the TRIUMPH
study (Translational Research Investigating Underlying Disparities
in Acute Myocardial Infarction Patients’ Health Status), the
1-year mortality was higher in patients with untreated depression
and not raised in patients with treated depression compared to
those without depression (Smolderen et al., 2017). Our DEPACS
(DEPression in Acute Coronary Syndrome) study group reported
findings from a randomised clinical trial (RCT), in which
24-week treatment with escitalopram compared with placebo was
associated with a lower risk of major adverse cardiac event
(MACE) after a median 8.4 years follow-up in patients with depres-
sion following recent ACS (Kim et al., 2018c). By extending this
analysed cohort, we aimed to investigate more comprehensively
whether depression screening, further diagnosis, and subsequent
treatment had differential associations with longer-term cardiac
outcomes following ACS. Other psychiatric diagnoses or problems
such as anxiety and suicidal ideation have also been associated with
cardiac outcomes and are commonly comorbid with depression.
We have published these issues in other publications (Kim et al.,
2018a, 2018b), hence we focused on depression issue here to
address the evidence gap in this area.
Methods
Study outline and participants
The analyses described in this study were carried out post-hoc
using data from a prospective observational study of patients
with ACS, Korean DEPACS (K-DEPACS), which also included
an RCT for patients with depressive disorder and ACS:
Escitalopram for DEPACS (EsDEPACS). The design and main
findings of K-DEPACS and EsDEPACS have been published
(Kim et al., 2018c, 2018a), and the eligibility criteria are described
in the online Supplementary material. Written informed consent
was collected for both studies, which were approved by the
Chonnam National University Hospital (CNUH) Institutional
Review Board. The outline and participant recruitment process
for analysis performed in this study are presented in Fig. 1.
K-DEPACS baseline evaluation
From 2006 to 2012, the K-DEPACS participants were consecu-
tively recruited from patients recently hospitalised with ACS
(N = 4809) at the Department of Cardiology of CNUH,
Gwangju, South Korea. Patients were treated by the study cardiol-
ogists based on international guidelines for the management of
ACS (Anderson et al., 2013). Those who met eligibility criteria
and agreed to participate comprised the K-DEPACS sample (N
= 1152), and were screened for depressive symptoms with the
Beck Depression Inventory (BDI) (Beck, Ward, Mendelson,
Mock, & Erbaugh, 1961) at baseline as inpatients within 2
weeks (mean 6.3 ± 2.4 days) post-ACS and thereafter as outpati-
ents every 4 weeks up to 12 weeks. The BDI was chosen as a
depression screen to retain consistency with a previous rando-
mised controlled trial for treating depression in ACS (Glassman
et al., 2002). Those screening positive (BDI>10, N = 501) at any
of these occasions received a clinical evaluation by the study psy-
chiatrists using the Mini-International Neuropsychiatric Interview
(MINI) (Sheehan et al., 1998), a structured diagnostic psychiatric
interview for Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) (American Psychiatric
Association, 1994), defining unipolar major or minor depressive
disorder categories as outputs.
Information was collected regarding characteristics that
could potentially affect cardiac outcomes (Jaffe et al., 2006;
Panteghini, 2004). Demographic data were obtained on age, sex,
education, marital status, living alone, housing and employment
status. Concerning psychiatric characteristics, the scores on
Hamilton Rating Scale for Depression (HAMD) (Hamilton,
1960) and Hospital Anxiety and Depression Scale depression anx-
iety subscale (HADS-A) (Bjelland, Dahl, Haug, & Neckelmann,
2002), and previous and family history of depression were
recorded. The following cardiovascular risk factors were ascer-
tained: diagnosed hypertension and diabetes mellitus, hyperchol-
esterolemia by fasting serum total cholesterol level (>200 mg/dL),
obesity (based on measured body mass index), reported current
smoking status and previous and family history of ACS. Cardiac
severity status was also characterised by Killip classification
(Killip & Kimball, 1967), left ventricular ejection fraction and
serum levels of troponin I and creatine kinase-MB. Frequencies
of the classes of cardiovascular medications used were recorded:
calcium channel blockers, nitrates, β-blockers, angiotensin-
converting enzyme inhibitors, angiotensin 2 receptor blocker, sta-
tins, aspirin, antiplatelets and diuretics.
The nested randomised controlled trial: EsDEPACS study
Of the 501 screen-positive participants, 55 had no depressive
disorder. Of the remaining 446 patients with a diagnosis of
major (N = 202) or minor (N = 244) depressive disorder, 300
who met the eligibility criteria and agreed to participate were
enrolled in a 24-week, double-blind, placebo-controlled RCT of
escitalopram, the EsDEPACS study (ClinicalTrial.gov registry
number: NCT00419471). Higher participation rates were noted
in those with more severe depressive symptoms, resulting in
major depressive disorder prevalences of 57.0% (85/149) in
escitalopram-allocated and 55.6% (84/151) in placebo-allocated
participants, compared to 22.6% (33/146) in the remaining
patients with the depressive disorder who were not randomised.
The first patient was enrolled in May 2007, and the last patient
completed follow-up evaluation in March 2013. Examinations
were scheduled at baseline, and in weeks 4, 8, 12, 16, 20 and 24
thereafter. The dose of the study drug was 10 mg/day initially
and could be changed (from 5 to 20mg/day) according to the
investigators’ clinical decision, taking into account response and
tolerability after the second evaluation. The mean (S.D.) doses at
the last visit were 7.6 (3.7) mg for the escitalopram group and
8.5 (3.9) mg for the placebo group. Adherence was checked by
pill counts at every visit, and was defined as acceptable if at least
75%. Adherence to medications was 93.3% and 95.4% in patients
receiving escitalopram and placebo, respectively. Depression treat-
ment, including antidepressant use other than study drugs, was
not allowed during the study period. With respect to the ethics
of the use of placebo in patients with depressive symptoms, the fol-
lowing considerations should be noted: (i) because of the lack of
evidence for the effect of depression treatment shortly following
ACS at the time the study was designed, the EsDEPACS trial
2 Jae-Min Kim et al.
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was judged both by funders and an independent ethics review
panel to be addressing an issue of clinical equipoise (Kim et al.,
2015a); (ii) besides providing study drugs, research psychiatrists
met with the patients for at least 30min at every visit and evalu-
ated their psychological symptoms using simple support and
reassurance after cardiology treatment; (iii) participants could
withdraw from the trial at any point and for any reason; (iv) for
participants without remission after the trial, further treatment
was facilitated when requested; (v) all participants were
approached for the evaluation of psychiatric outcomes 1 year
after baseline evaluation (Kim et al., 2015b). The details and
main results of this trial have been published previously (Kim
et al., 2015a), in which escitalopram was superior to placebo in
treating depression without significant difference in adverse
events. The remaining 146 participants who did not meet the eli-
gibility criteria or declined participation in the trial received con-
ventional medical treatment for ACS only (MTO). The MTO and
screen-positive but had no depressive disorder participants were
recommended treating depressive symptoms wherever possible.
Long-term cardiac outcomes
Comprehensive evaluations for cardiac outcomes were conducted
for data on hospital admissions, deaths, recurrent MI and
percutaneous coronary intervention (PCI). To enable non-
hierarchic endpoint analyses, all patients were followed for the
evaluation point of interest or until death. The primary endpoint
was a MACE, which was a composite of all-cause mortality, MI
and PCI (excluding non-emergent PCIs). Secondary endpoints
were all-cause mortality, cardiac death (defined as sudden death
when no other explanation was available, death from arrhythmias
or after MI or heart failure, or death caused by heart surgery or
endocarditis), MI and PCI. An independent endpoint committee
composed of study cardiologists adjudicated all potential events,
blind to participants’ depression status.
Statistical analysis
According to the depression screening, diagnosis and treatment
status at baseline, participants were divided into five groups:
651 screening negative, 55 screening positive but not found to
have a depressive disorder, 149 with depressive disorder rando-
mised to escitalopram, 151 with depressive disorder randomised
to placebo and 146 with depressive disorder receiving MTO.
Demographic and clinical characteristics at baseline were com-
pared between the five groups using analysis of variance or χ2
tests with post-hoc Scheffe’s tests, or using individual pairwise
post-hoc comparisons between the five groups as appropriate.
149 assigned to receive 
escitalopram
146 refused participate and 
received medical treatment only
151 assigned to receive 
placebo
4809 patients with ACS screened
3657 excluded
3285 unsuitable criteria
2013 In severe physically ill state
636 Inability to complete questionnaires
333 Didn’t meet ACS criteria by investigation
234 Had significant laboratory abnormalities
36 Had uncontrolled hypertension
33 Aged over 85
372 refused participation
1152 patients had BDI and MINI 
(K-DEPACS)
446 met depressive disorder  criteria:
202 major and 244 minor depression
300 randomised to the double blind trial 
to treat depressive disorder (EsDEPACS)
149 followed 5~12 years   
after the index ACS
651 followed 5~12 years   
after the index ACS
146 followed 5~12 years   
after the index ACS
151 followed 5~12 years   
after the index ACS
55 followed 5~12 years   
after the index ACS
55 didn’t meet depressive 
disorder criteria
501 had BDI scores over 10651 had BDI scores 10 or less
Depressive disorder on 
escitalopram (E)
Depressive disorder  on placebo
(P)
Depressive disorder  on medical 
treatment only (M)
Screening positive but no 
depressive disorder (S)
Screening negative
(N)
Fig. 1. Study outline and participants recruitment process. ACS, acute coronary syndrome; K-DEPACS, Korean DEPression in Acute Coronary Syndrome study; BDI,
Beck Depression Inventory; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition; EsDEPACS, Escitalopram for DEPression in Acute Coronary
Syndrome study.
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Characteristics significantly associated with group status ( p <
0.05) and/or with potential effects on MACE were used as covari-
ates a priori in further adjusted analyses. For investigating the
effects of depression screening and diagnosis on long-term
MACE in ACS, Kaplan–Meier curves were constructed and the
cumulative proportion of MACE by negative v. positive screening
status (and further by screening positive with v. without depres-
sive disorder status) at baseline was compared using the log-rank
tests. Cox proportional hazards models were used to assess the
time to MACE after adjustment for the potential covariates
described above. For investigating subsequent depression treat-
ment effects according to treatment allocations, the same Cox
proportional hazards models were used among the four depres-
sive screening-positive groups with individual pairwise post-hoc
comparisons. Sensitivity analyses were carried out excluding
patients taking antidepressants at the 1-year post-ACS examin-
ation to exclude the possible medication effects on long-term car-
diac outcomes. To adjust for an overall type I error rate of p < 0.05
for multiple comparisons, Bonferroni corrections were conducted
(five comparisons: a primary and four secondary endpoints; 0.05/
5 = 0.01) in the long-term cardiac outcome analyses. Statistical
analyses were carried out using SPSS 21.0 software.
Results
Baseline characteristics for the five comparison groups
Baseline characteristics between the five groups are compared in
Table 1. Significant group differences were found in age, sex, edu-
cation, marital status, living alone, accommodation, employment
status, scores on HAMD and HADS-A, hypertension, diabetes,
smoking status and family history of ACS (all p < 0.05).
Considering these results and previous research (Bjelland et al.,
2002; Killip and Kimball, 1967), 10 variables (see footnotes of
Tables 2 and 3) were included as covariates in subsequent ana-
lyses. Results of post-hoc comparisons are summarised in the
last column of Table 1. In particular, the mean scores on
HAMD and HADS-A in the ‘depressive disorder on MTO’
group were significantly lower than in those with depressive dis-
order receiving escitalopram or placebo, but were similar to those
screening positive but with no depressive disorder diagnosis.
MACE occurrences according to depression screening and
diagnosis status
In 2017, all participants were followed for 5–12 years or until they
died [median; mean (S.D.) follow-up = 8.4; 8.7 (1.5) years]. The
primary endpoint (composite MACE) occurred in 446 (38.7%)
participants. Considering secondary endpoints, all-cause mortal-
ity occurred in 211 (18.3%), cardiac death in 111 (9.6%), MI in
110 (9.5%) and PCI in 162 (14.1%) participants. Cumulative com-
posite MACE incidences in the five exposure groups are illustrated
in Fig. 2 [screening negative 29.6% (193/651), screening positive
but no depressive disorder 43.6% (24/55), depressive disorder
on escitalopram 40.9% (61/149), depressive disorder on placebo
53.6% (81/151) and depressive disorder on MTO 59.6% (87/
146)]. Significant group differences were found across all five
exposure categories and between the four depression screen-
positive groups. Antidepressants were being taken by 19 partici-
pants (eight screening negative, one screening positive but no
depressive disorder, five on depressive disorder on escitalopram,
three on depressive disorder on placebo and two on depressive
disorder on MTO) at the 1-year follow-up point. When the
same analyses were repeated after excluding these participants,
the results were not changed substantially. The incidences of
the composite MACE outcome and its individual components
are compared in Table 2 according to depression screen-
positive/negative status and between the screen-positive sub-
groups with/without depressive disorder diagnostic criteria. In
the total sample, participants screening positive for depressive dis-
order had significantly higher hazards of composite and all indi-
vidual MACE components except for MI compared to those
screening negative after full adjustment. Compared to the screen-
negative group, those screening positive but not fulfilling diagnos-
tic criteria for depressive disorder retained significantly higher
hazards of composite MACE, all-cause mortality and cardiac
death; and those screening positive with a depressive disorder
diagnosis had significantly higher hazards of composite and all
individual MACE components except for MI. However, in the
screen-positive group, no significant differences were found in
MACE incidences between those with and without diagnostic
criteria for depressive disorder.
MACE occurrences according to subsequent depression
treatment status
Comparisons of the four depression screen-positive subgroups
after the same adjustments are described in Table 3. Significant
group differences in all MACE outcomes were found. In post-hoc
comparisons ( p < 0.05), those randomised to escitalopram dis-
played better outcomes in composite MACE and PCI compared
to both those randomised to placebo and those receiving MTO,
and lower all-cause mortality and MI compared to those receiving
MTO. Participants randomised to placebo had better outcomes in
composite MACE and all-cause mortality compared to those
receiving MTO. The screen-positive group without diagnostic cri-
teria for the depressive disorder had higher all-cause mortality
compared to participants randomised to escitalopram, but did
not differ significantly from other depression treatment groups.
Discussion
In this median 8.4-year follow-up of patients with recent ACS,
screening positive for depression on the BDI was associated
with worse long-term cardiac outcomes, even in the cases who
did not fulfil diagnostic criteria for depressive disorder. Of
patients in this screen-positive group, those randomised to 24
weeks of escitalopram treatment experienced better cardiac out-
comes than those randomised to placebo and those with the diag-
nosed depressive disorder who were not randomised and received
MTO instead. This latter MTO group had worse outcomes than
those receiving placebo, despite having significantly milder
depressive symptoms at baseline.
In this study, worse long-term cardiac outcomes in the screen-
positive group were largely consistent with previous reports using
depressive symptom scales for categorising depression (Lesperance,
Frasure-Smith, Talajic,&Bourassa, 2002).Ameta-analysis of 26 stud-
ies of various heart diseases, cardiac outcomes and follow-up dur-
ation, using depressive symptom scales estimated the hazards ratio
associated with depressive symptoms to be 1.92 (Nicholson et al.,
2006). The equivalent hazards ratio in the cohort described here
was 2.15, and thus higher than the meta-analysed pooled result.
The cohort in our study was a homogeneous diagnostic group with
4 Jae-Min Kim et al.
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Table 1. Baseline characteristics by depression screening, diagnosis and treatment status in 1152 patients with acute coronary syndrome (ACS)
Screening
negative
(N)
(N = 651)
Screening
positive but
no
depressive
disorder (S)
(N = 55)
Depressive
disorder on
escitalopram
(E) (N = 149)
Depressive
disorder on
placebo (P)
(N = 151)
Depressive
disorder on
medical
treatment
only (M)
(N = 146)
Statistics for
group
differencesa
Post-hoc
comparisons
( p < 0.05)
Demographic characteristics
Age, mean (S.D.) year 58.3 (11.5) 55.0 (9.4) 60.0 (11.2) 60.1 (10.5) 58.3 (11.6) F = 2.753
p = 0.027
n-s
Sex, N (%) men 514 (79.0) 44 (80.0) 89 (59.7) 93 (61.6) 84 (57.5) χ2 = 51.116
p < 0.001
N,S > E,P,M
Education, mean (S.D.)
year
10.2 (4.8) 9.4 (4.4) 9.4 (4.2) 9.2 (4.1) 9.0 (5.1) F = 3.166
p = 0.013
n-s
Unmarried marital
status, N (%)
84 (12.9) 10 (18.2) 18 (12.1) 29 (19.2) 35 (24.0) χ2 = 14.698
p = 0.005
N,E < M
Living alone, N (%) 54 (8.3) 6 (10.9) 12 (8.1) 16 (10.6) 24 (16.4) χ2 = 9.706
p = 0.046
N,E < M
Rented
accommodation, N (%)
73 (11.2) 13 (23.6) 21 (14.1) 34 (22.5) 28 (19.2) χ2 = 19.582
p = 0.001
N < S,P,M
Unemployed status, N
(%)
217 (33.3) 22 (40.0) 71 (47.7) 73 (48.3) 67 (45.9) χ2 = 21.939
p < 0.001
N < E,P,M
Psychiatric characteristics
HAMD, mean (S.D.)
score
3.2 (2.3) 7.6 (3.1) 15.9 (4.8) 15.6 (4.8) 10.9 (3.4) F = 783.607
p < 0.001
N < S,M < E,P
HADS-A, mean (S.D.)
score
3.5 (1.2) 4.9 (1.2) 6.3 (2.5) 6.2 (2.4) 4.3 (1.89) χ2 = 136.231
p < 0.001
N < S,M < E,P
Previous depression,
N (%)
20 (3.1) 1 (1.8) 6 (4.0) 7 (4.6) 8 (5.5) χ2 = 3.013
p = 0.556
n-s
Family history of
depression, N (%)
16 (2.5) 2 (3.6) 5 (3.4) 6 (4.0) 4 (2.7) χ2 = 1.310
p = 0.860
n-s
Cardiac risk factors, N (%)
Hypertension 283 (43.5) 21 (38.2) 90 (60.4) 94 (62.3) 68 (46.6) χ2 = 29.018
p < 0.001
N,S,M < E,P
Diabetes mellitus 116 (17.8) 6 (10.9) 44 (29.5) 41 (27.2) 28 (19.2) χ2 = 17.746
p = 0.001
N,S < E,P
M < E
Hypercholesterolemia 324 (49.8) 26 (47.3) 73 (49.0) 71 (47.0) 78 (53.4) χ2 = 1.404
p = 0.844
n-s
Obesity 283 (43.5) 23 (41.8) 59 (39.6) 65 (43.0) 60 (41.1) χ2 = 0.911
p = 0.923
n-s
Current smoker 261 (40.1) 26 (47.3) 44 (29.5) 42 (27.8) 44 (30.1) χ2 = 16.981
p = 0.002
N,S > E,P,M
Previous ACS 19 (2.9) 4 (7.3) 8 (5.4) 11 (7.3) 8 (5.5) χ2 = 8.298
p = 0.081
n-s
Family history of ACS 11 (1.7) 6 (10.9) 9 (6.0) 8 (5.3) 5 (3.4) χ2 = 20.142
p < 0.001
N < S,E,P
S > M
Current cardiac status
Killip class >1, N (%) 114 (17.5) 5 (9.1) 24 (16.1) 35 (23.2) 28 (19.2) χ2 = 6.327
p = 0.176
n-s
LVEF, mean (S.D.)
percent
61.7 (11.0) 58.2 (13.8) 60.4 (11.0) 61.9 (10.4) 60.1 (12.6) F = 1.983
p = 0.095
n-s
Troponin I, mean
(S.D.) mg/dL
9.4 (16.0) 10.2 (17.9) 9.7 (8.5) 9.7 (8.0) 9.6 (16.0) F = 0.060
p = 0.993
n-s
CK-MB, mean (S.D.)
mg/dL
16.4 (39.5) 23.9 (54.6) 17.2 (22.0) 16.3 (20.8) 18.6 (42.3) F = 0.607
p = 0.658
n-s
(Continued )
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comprehensive cardiac outcomes and longer follow-up, all of which
are recommended in cardiac outcome studies (Galløe et al., 2008).
Through the further application of a diagnostic protocol for
depressive disorder, it was possible to discriminate the group
who screened positive for depression but did not fulfil diagnostic
criteria for depressive disorder. As far as we are aware, long-term
cardiac outcomes in this particular group have not previously
been evaluated specifically. The strengths of the associations
with adverse outcomes were not statistically different in this
group compared to those with diagnosed depressive disorder.
However, statistically significant associations were found for
fatal rather than non-fatal outcomes, partly consistent with a pre-
vious research report that even minimal symptoms of depression
increase the mortality risk after acute MI (Bush et al., 2001).
These results suggest that screening of depression for identifying
even minor depressive symptoms might be meaningful in terms
of predictive values in patients with ACS. They provide some sup-
port for further formal diagnostic assessment for depressive dis-
order which would be beyond current recommendations of
AHA Science Advisory (Lichtman et al., 2008); however, drawing
conclusions should be cautious, since there were no direct com-
parisons between a screened and non-screened group in this
study, and the size of this group was small, which may increase
the possibility of type II error.
The cumulative incidence of composite MACE was signifi-
cantly lower in people with depressive disorder randomised to
escitalopram group (40.9%) compared both to those randomised
to placebo (53.6%) and those not randomised and receiving MTO
(59.6%). In this study cohort, we have previously reported that
escitalopram treatment for depression after a recently developed
ACS was associated with better psychiatric outcomes including
depressive symptoms, sleep, social function and quality of life at
the 24-week endpoint compared to placebo (Kim et al., 2015a,
2015b) as well as at 1 year after the index ACS compared to pla-
cebo and MTO (Kang et al., 2015). Recently, we also reported that
escitalopram treatment was associated with better long-term car-
diac outcomes compared with placebo (Kim et al., 2018c).
Moreover in the present study, those randomised to escitalopram
had significantly lower all-cause mortality even compared to the
screen-positive group without diagnostic criteria for depressive
disorder. All these results suggest that successful treatment of
depression and thereby improvement of psychiatric outcomes
after the recent ACS could modify the long-term prognosis of
ACS. Our findings are supported by previous observations that
non-remission of depression is associated with unhealthy behav-
iour including sedentary lifestyle and treatment non-adherence to
cardiovascular drugs, which are predictors of worse ACS progno-
sis (Whooley et al., 2008). One consideration is that the
Enhancing Recovery in Coronary Heart Disease Patients
(ENRICHD) trial found the intervention (9 months of cognitive
behavioural therapy with or without 12 months of antidepres-
sants) had significant beneficial effects on improving depressive
symptoms compared to usual care among 2481patients with
depression following MI (Berkman et al., 2003), but nonetheless
found no difference in cardiac outcomes over a 29-month
follow-up between the two groups (van Melle et al., 2007). A
meta-analysis of 16 studies of depression following ACS found
that differences in MACE occurrence became prominent over
Table 1. (Continued.)
Screening
negative
(N)
(N = 651)
Screening
positive but
no
depressive
disorder (S)
(N = 55)
Depressive
disorder on
escitalopram
(E) (N = 149)
Depressive
disorder on
placebo (P)
(N = 151)
Depressive
disorder on
medical
treatment
only (M)
(N = 146)
Statistics for
group
differencesa
Post-hoc
comparisons
( p < 0.05)
Cardiovascular medications
Calcium channel
blockers
204 (31.3) 18 (32.7) 51 (34.2) 59 (39.1) 45 (30.8) χ2 = 1.829
p = 0.767
n-s
Nitrates 504 (77.4) 42 (76.4) 116 (77.9) 114 (75.5) 102 (69.9) χ2 = 0.560
p = 0.967
n-s
β-blockers 471 (72.4) 42 (76.4) 108 (72.5) 106 (70.2) 109 (74.7) χ2 = 0.183
p = 0.996
n-s
Angiotensin-converting
enzyme inhibitors
201 (30.9) 18 (32.7) 45 (30.2) 51 (33.8) 48 (32.9) χ2 = 0.394
p = 0.983
n-s
Angiotensin 2
receptor blocker
329 (50.4) 27 (49.1) 76 (51.0) 76 (50.3) 74 (50.7) χ2 = 0.021
p = 0.999
n-s
Statins 482 (74.0) 41 (74.5) 119 (79.9) 116 (76.8) 108 (74.0) χ2 = 0.355
p = 0.986
n-s
Aspirin 603 (92.7) 51 (92.7) 132 (88.6) 136 (90.1) 135 (92.5) χ2 = 0.146
p = 0.997
n-s
Antiplatelets 502 (77.1) 45 (81.8) 113 (75.8) 113 (74.8) 112 (76.7) χ2 = 0.158
p = 0.997
n-s
Diuretics 123 (18.9) 11 (20.0) 32 (21.5) 29 (19.2) 25 (17.1) χ2 = 0.650
p = 0.957
n-s
HAMD, Hamilton Rating Scale for Depression; HADS-A, Hospital Anxiety and Depression Scale anxiety subscale; LVEF, left ventricular ejection fraction; CK-MB, creatine kinase-MB.
aAnalysis of variance or χ2 tests as appropriate.
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longer follow-up intervals (Meijer et al., 2013); thus our positive
findings probably will be due to the longer follow-up period.
An interesting finding is that the depressive disorder on MTO
group showed the worst long-term cardiac outcomes, compared
not only to the escitalopram but also to the placebo group despite
the fact that the group receiving MTO had less severe depressive
and anxiety symptoms at baseline (Table 1). This may be due to
those with mild depressive symptoms being more likely to refuse
to participate. On the other hand, it may be related to generic
input provided in the RCT. As stated earlier, the research psychia-
trists met the patients allocated to escitalopram or placebo at least
30 min at every visit for evaluating psychological symptoms with
simple supports and reassurance after the cardiologists’ treatment,
while the MTO group was only formally provided with cardiolo-
gists’ treatment. The input received by both treatment and pla-
cebo groups in the RCT may thus have similarities to
Table 2. Effects of depression screening and diagnosis status on long-term cardiac outcomes in 1152 patients with acute coronary syndrome (ACS)
Cardiac outcomes
Group by depression
screening and
diagnosis status
N
patient
N (%)
event
All participants (N = 1152)
Screening positive participants
(N = 501)
AHR (95% CI)a p AHR (95% CI)a p
Major adverse
cardiac event
Screening negative 651 193
(29.6)
Ref
Screening positive 501 253
(50.5)
2.16 (1.64–2.84) <0.001
No depressive
disorder
55 24
(43.6)
2.04 (1.28–3.27) 0.003 Ref
Present depressive
disorder
446 229
(51.3)
2.18 (1.64–2.88) <0.001 1.06 (0.69–1.65) 0.822
All cause death Screening negative 651 86
(13.2)
Ref
Screening positive 501 125
(25.0)
2.26 (1.52–3.36) <0.001
No depressive
disorder
55 14
(25.5)
2.85 (1.50–5.40) 0.001 Ref
Present depressive
disorder
446 111
(24.9)
2.18 (1.47–3.27) <0.001 0.79 (0.45–1.44) 0.435
Cardiac death Screening negative 651 41
(6.3)
Ref
Screening positive 501 70
(14.0)
2.31 (1.35–3.96) 0.002
No depressive
disorder
55 9
(16.4)
3.03 (1.35–6.81) 0.007 Ref
Present depressive
disorder
446 61
(13.7)
2.20 (1.29–3.81) 0.005 0.77 (0.36–1.62) 0.459
Myocardial
infarction
Screening negative 651 47
(7.2)
Ref
Screening positive 501 63
(12.6)
1.59 (0.90–2.79) 0.108
No depressive
disorder
55 4 (7.3) 0.95 (0.33–2.88) 0.900 Ref
Present depressive
disorder
446 59
(13.2)
1.68 (0.95–2.97) 0.081 1.80 (0.63–5.28) 0.282
Percutaneous
coronary
intervention
Screening negative 651 73
(11.2)
Ref
Screening positive 501 89
(17.8)
1.92 (1.23–3.06) 0.006
No depressive
disorder
55 6
(10.9)
1.41 (0.57–3.45) 0.459 Ref
Present depressive
disorder
446 83
(18.6)
2.01 (1.26–3.24) 0.003 1.32 (0.57–3.12) 0.540
aAdjusted hazards ratio (95% confidence interval) [AHR (95% CI)] after adjustment for age, sex, marital status, employment, scores on Hamilton Rating Scale for Depression and Hospital
Anxiety and Depression Scale anxiety subscale, hypertension, diabetes, smoking and left ventricular ejection fraction.
Values in bold type represent statistical significance after Bonferroni correction.
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collaborative care, which has been cited as effective for treating
psychological symptoms and for reducing cardiac symptoms dur-
ing the treatment period (Davidson et al., 2010). The beneficial
effect of placebo over MTO may be due to this kind of active psy-
chological care with higher levels of attention as well as the pla-
cebo effect itself. Similar findings have been observed in
patients with major depressive disorder, in that treatment enrol-
ment with pill-taking, regardless of whether this involves the
active drug or placebo, promotes therapeutic alliance and
increased response compared to conventional treatment
(Leuchter, Hunter, Tartter, & Cook, 2014). Related to this, the dif-
ference in MACE between the groups was driven largely by PCI,
suggesting that patients closer to therapy might have interacted in
a more consistent basis with physicians, thus potentially account-
ing for the better outcomes.
Based on our findings, several suggestions can be proposed.
First, routine depression screening is recommended for identify-
ing a group at risk of long-term adverse cardiac outcomes
Table 3. Effects of depression treatment status on long-term cardiac outcomes in 501 patients with acute coronary syndrome (ACS)
Cardiac
outcomes, N (%)
Screening
positive but no
depressive
disorder (S)
(N = 55)
Depressive
disorder on
escitalopram (E)
(N = 149)
Depressive
disorder on
placebo (P)
(N = 151)
Depressive disorder
on medical
treatment only (M)
(N = 146)
Statistics for
group
differencesa
Post-hoc
comparisons
( p < 0.05)
Major adverse
cardiac event
24 (43.6) 61 (40.9) 81 (53.6) 87 (59.6) Wald = 43.276
p < 0.001
E < P<M
All-cause
mortality
14 (25.5) 31 (20.8) 37 (24.5) 43 (29.5) Wald = 18.157
p < 0.001
S > E
E,P < M
Cardiac death 9 (16.4) 16 (10.7) 20 (13.2) 25 (17.1) Wald = 9.162
p = 0.002
n-s
Myocardial
infarction
4 (7.3) 12 (8.1) 12 (15.2) 23 (15.8) Wald = 8.691
p = 0.003
E < M
Percutaneous
coronary
intervention
6 (10.9) 19 (12.8) 30 (19.9) 34 (23.3) Wald = 17.431
p < 0.001
E < P,M
aCox proportional hazard tests after adjusted age, sex, marital status, employment, scores on Hamilton Rating Scale for Depression and Hospital Anxiety and Depression Scale anxiety
subscale, hypertension, diabetes, smoking and left ventricular ejection fraction.
Patients can have more than one event.
Values in bold type represent statistical significance after Bonferroni correction.
0 1 2 3 4 5 6 7 8 9 10 11 12
0
10
20
30
40
50
60
70
Patients at risk
Depressive disorder on medical treatment only 146 116 100 94 85 78 71 66 46 29 22 12 8
Depressive disorder on placebo 151 131 122 109 95 85 71 60 48 34 23 12 11
Depressive disorder on escitalopram 149 134 123 117 112 106 87 68 54 40 29 16 15
Screening positive but no depressive disorder 55 49 43 40 38 37 35 30 30 28 25 15 6
Screening negative 651 591 570 552 533 512 492 445 343 254 174 117 59
Log rank P-value<0.001 in all participants;
P-value=0.004 in screening positive participants
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Fig. 2. Cumulative incidence (%) of major adverse cardiac events (MACE) by time (years) in 1152 patients with acute coronary syndrome (ACS).
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(approximately two times higher based on previous findings and
our own) in all recently developed ACS patients. Although direct
ACS treatment is urgent, intensive and required to prevent early
mortality, there remains potential time to administer simple
depression screening scales following initial stabilisation and
before hospital discharge. Second, depression treatment with anti-
depressants, particularly with escitalopram (Kim et al., 2015a),
can be proposed for patients with depressive disorders. The treat-
ment may reduce the depressive symptoms as well as improve the
long-term cardiac outcomes (Kim et al., 2018c). Third, for
patients with depressive disorders but who do not want to take
antidepressants, collaborative care with psychiatric personnel
could be considered. Since integrated collaborative care has
been shown to be effective for reducing both depressive and car-
diac symptoms during the treatment period (Meijer et al., 2013),
long-term follow-up study results are anticipated. Fourth, for
those who have depressive symptoms but do not accept any psy-
chiatric help, more careful monitoring with regular examinations
for cardiovascular status might reduce the occurrence of MACE
(Carney et al., 2009), while these need further investigation.
Effectiveness of long-term cardiac outcomes can be approxi-
mated from the present findings, summarised visually in Fig. 3.
Composite MACE occurred in 446 (38.7%) of 1152 participants
with ACS during a median 8.4-year follow-up. After depression
screening and diagnosis, 446 patients were diagnosed as having
depressive disorders. If all these patients with depressive disorders
received just conventional MTO, the number of MACE expected
in all participants would be 483 [41.9%; 193 in those screening
negative, plus 24 in those screening positive but with no depres-
sive disorder, plus 266 (59.6%) in the 446 with depressive dis-
order]. More conservatively, if it is assumed that all patients
with depressive disorder received placebo, the number of MACE
expected in all participants would be 456 [39.6%; 193 in those
screening negative, plus 24 in those screening positive but with
no depressive disorder, plus 239 (53.6%) in the 446 with depres-
sive disorder]. However, if all these patients received escitalopram,
the number of MACE expected in all participants would be 399
[34.6%; 193 in those screening negative, plus 24 in those screening
positive but with no depressive disorder, plus 182 (40.9%) in the
446 with depressive disorder]. Summing up, if the depression
screening–diagnosis–treatment package were to be administered
to a hypothetical 1000 patients with recent ACS, the number of
MACE instances over a 5–12-year period (i.e. that covered in
our study) could be reduced by 73 or 50 compared, respectively,
to MTO- or placebo-equivalent conditions. Additionally, the
effects of interventions for depressive symptoms on long-term
cardiac outcomes in the screen-positive group without diagnostic
criteria for depressive disorder have not been evaluated yet,
although would be worth investigating considering the negative
impact of depressive symptoms reported by previous research
and our own study.
Limitations should also be considered. First, recruitment was
carried out at a single site, which may limit the generalisability
of the present findings, although a single-centre study has poten-
tial strengths in terms of consistency in evaluation and treatment.
Second, the MTO group was not randomly assigned but was
formed of those patients with depressive disorder who refused
or were non-eligible to take part in the clinical trial, since the pre-
sent analyses were not pre-planned. This group is thus not equiva-
lent at baseline to the randomised groups and subject to selection
bias; specifically, the baseline features of the MTO group indicate
lower depression and anxiety symptoms. However, this bias may
obscure rather than magnify the findings, and all data on longitu-
dinal effects were adjusted for baseline scores on depression and
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Fig. 3. Approximated cumulative incidence (%) of major adverse cardiac events (MACE) by depression treatment status in patients with acute coronary syndrome
(ACS). If the depression screening–diagnosis–treatment package were to be administered to a hypothetical 1000 patients with recent ACS, the number of MACE
instances over a median 8.4-year follow-up period could be reduced by 73 or 50 compared respectively to medical treatment only or placebo-equivalent conditions.
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anxiety symptoms. Future studies are needed with randomisation
or other means to evaluate (e.g. by propensity-matching) MTO as
an intervention to clarify this issue. Third, antidepressants use
after the RCT was investigated only one time at the 1-year
follow-up point, although the number was small (19 participants).
Related to this, no attempt was made to investigate the effect of
non-pharmacologic treatment for depression or other mental
health conditions during the follow-up period, although within
the Korean healthcare system this would be relatively uncommon.
Conclusion
Depressive disorder can be reasonably identified by routine
screening in all patients with recent ACS and subsequent appro-
priate treatment should be recommended to those who screen
positive and meet diagnostic criteria, which could improve long-
term cardiac outcomes. Considering service impact, the routine
administration of depression screening scales need not require
lengthy or expensive assessments, although further treatment of
depression does indeed give rise to potential time and cost impli-
cations. However, it has been reported that ACS is the most costly
disease than any diagnostic group (Benjamin et al., 2018). Our
findings suggest that depression screening and treatment might
significantly reduce MACE occurrence, but further evaluation is
needed to estimate cost-effectiveness in more detail.
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